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GRAPHICAL ABSTRACT
ACH: acrodermatitis continua of Hallopeau; GPP: generalised pustular psoriasis; PPP: palmoplantar pustulosis; PV: psoriasis vulgaris
Clinical and genetic differences between pustular psoriasis subtypes
863 pustular psoriasis patients
Generalised Pustular Psoriasis, n=251
Acrodermatitis Continua of Hallopeau, n=28
PalmoPlantar Pustulosis, n=560
Multiple diagnoses, n=24
Clinical features
whole cohort, n = 863
Genetic features
cohort subset, n = 475
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ACH: Acrodermatitis continua of Hallopeau
ERASPEN: European Rare and Severe Psoriasis Expert Network
GPP: Generalized pustular psoriasis
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2 TWELVES ET ALBackground: The term pustular psoriasis indicates a group of
severe skin disorders characterized by eruptions of neutrophil-
filled pustules. The disease, which often manifests with
concurrent psoriasis vulgaris, can have an acute systemic
(generalized pustular psoriasis [GPP]) or chronic localized
(palmoplantar pustulosis [PPP] and acrodermatitis continua of
Hallopeau [ACH]) presentation. Although mutations have been
uncovered in IL36RN and AP1S3, the rarity of the disease has
hindered the study of genotype-phenotype correlations.
Objective: We sought to characterize the clinical and genetic
features of pustular psoriasis through the analysis of an
extended patient cohort.
Methods: We ascertained a data set of unprecedented size,
including 863 unrelated patients (251 with GPP, 560 with PPP,
28 with ACH, and 24 with multiple diagnoses). We undertook
mutation screening in 473 cases.
Results: Psoriasis vulgaris concurrence was lowest in PPP (15.8%
vs 54.4% in GPP and 46.2% in ACH, P < .0005 for both), whereas
themean age of onset was earliest inGPP (31.0 vs 43.7 years in PPP
and51.8 years inACH,P<.0001 forboth).Thepercentage of female
patients was greater in PPP (77.0%) than in GPP (62.5%;
P5 5.83 1025). The same applied to the prevalence of smokers
(79.8% vs 28.3%, P < 10215). Although AP1S3 alleles had similar
frequency (0.03-0.05) across disease subtypes, IL36RNmutations
were less common in patients with PPP (0.03) than in those with
GPP (0.19) andACH (0.16; P5 1.93 10214 and .002, respectively).
Importantly, IL36RN disease alleles had a dose-dependent effect on
age of onset in all forms of pustular psoriasis (P5 .003).
Conclusions: The analysis of an unparalleled resource revealed
key clinical and genetic differences between patients with PPP and
those with GPP. (J Allergy Clin Immunol 2018;nnn:nnn-nnn.)
Key words: Generalized pustular psoriasis, palmoplantar pustulo-
sis, acrodermatitis continua of Hallopeau, IL36RN, AP1S3, geno-
type-phenotype correlation
The term pustular psoriasis refers to a group of severe
inflammatory skin disorders manifesting with repeated eruptions
of painful neutrophil-filled pustules. These conditions can present
with acute episodes of skin pustulation and systemic upset
(generalized pustular psoriasis [GPP]) or chronic pustular
eruptions that affect the palms and soles (palmoplantar pustulosis
[PPP]) or the tips of fingers and toes (acrodermatitis continua of
Hallopeau [ACH]). Of note, all forms of the disease can be
complicated by concurrent psoriasis vulgaris (PV).1
We and others have shown that mutations of the gene encoding
the IL-36 receptor antagonist (IL36RN) are associated with GPP.2,3Supported by the Department of Health through the National Institute for Health
Research (NIHR) BioResource Clinical Research Facility and comprehensive
Biomedical Research Centre awards to Guy’s and St Thomas’ NHS Foundation Trust
in partnership with King’s College London and King’s College Hospital NHS
Foundation Trust (guysbrc-2012-1) and to the NIHR-Newcastle Biomedical Research
Centre. This work was funded by a Medical Research Council (MRC) Stratified
Medicine award (MR/L011808/1; to J.N.B., F.C., and C.H.S.) and by the Efficacy and
Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership (grant
EME 13/50/17 to C.H.S., F.C., J.N.B., C.E.M.G., and N.R.). N.R. is also supported by
the Newcastle MRC/EPSRC Molecular Pathology Node. S.T. is supported by the
King’s Bioscience Institute and the Guy’s and St Thomas’ Charity Prize PhD
Programme in Biomedical and Translational Science. The European Rare and Severe
Psoriasis Expert Network is funded by a PPRC grant from the European Association of
Dermatology and Venereology (EADV; to A.A.N. and J.N.B.). The views expressed inAlthough these defects are observed mostly in the homozygous or
compound heterozygous state, a number of patients carrying single
heterozygous changes have also been reported.4
Disease alleles associated with GPP have been identified
subsequently in AP1S3 (encoding a subunit of the adaptor protein
1 complex)5 and CARD14 (encoding a keratinocyte nuclear factor
kB adaptor protein).6 Of note, IL36RN, CARD14, and AP1S3
mutations have also been described in patients with PPP and those
with ACH, demonstrating a shared genetic basis for pustular forms
of psoriasis.5,7,8 Patients harboring disease alleles at 2 distinct loci
(IL36RN and AP1S3; IL36RN and CARD14) have also been
reported.9,10 Thus an increasingly complex picture is emerging
with evidence of substantial genetic heterogeneity, pleiotropy (the
phenomenonwhereby a single gene can influencemore than 1 trait),
and digenic inheritance.
In this context analysis of genotype-phenotype correlations
would facilitate stratification of patient cohorts and streamline the
genetic diagnosis of disease subtypes. However, rigorous studies
have been hindered by the rarity of pustular psoriasis, which has
prevented the ascertainment and standardized phenotyping of
sizeable patient resources.
Here we sought to address this issue through formation of a
multicenter consortium. We brought together 8 tightly pheno-
typed patient cohorts through a collaboration with the European
Rare and Severe Psoriasis Expert Network (ERASPEN). This
enabled us to ascertain a unique clinical resource, including 863
unrelated cases and exceeding by nearly 3-fold the size of any
published data set. Analysis of this extended cohort revealed very
significant differences in the clinical and genetic features of
pustular psoriasis subtypes. Specifically, it demonstrated that PPP
differs from ACH and GPP in terms of patients’ demographics,
disease presentation, and underlying genetic abnormalities.METHODS
Patient ascertainment
This research was carried out in accordance with the principles of the
Declaration of Helsinki and was approved by the ethics committees ofthis publication are those of the authors and not necessarily those of the MRC, NHS,
NIHR, or Department of Health.
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TABLE I. Summary description of the patient cohort
Ethnicity Sex Clinical diagnosis
TotalEuropean Asian African Other* Female Male Unknown ACH PPP GPP ACH 1 GPP ACH 1 PPP GPP 1 PPP
Total 591 161 78 33 620 233 10 28 560 251 9 4 11 863
*Includes unknown ethnicity (n 5 19), mixed ethnicity (n 5 4), and Middle Eastern (n 5 4), Finnish (n 5 2), Filipino (n 5 1), Hispanic (n 5 1), Jamaican (n 5 1), and Romani
(n 5 1) ethnicity.
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TWELVES ET AL 3participating institutions. Written informed consent was also obtained from all
participants. The study aligned 8 patient cohorts (n 5 863) recruited in the
reference centers listed in Table E1 in this article’s Online Repository at
www.jacionline.org. The largest resource (n 5 255 British and Irish cases)
was provided by St John’s Institute of Dermatology (London, United Kingdom)
and combined a historical data set (n 5 177) with patients ascertained
prospectively (n 5 78) through the Anakinra in Pustular Psoriasis,
Response in a Controlled Trial (APRICOT) clinical trial (EudraCT no.
2015-003600-23) and its sister mechanistic study, Pustular Psoriasis,
Elucidating Underlying Mechanisms (PLUM). An additional 40 affected
subjects (listed as ‘‘others’’ in Table E1) were recruited outside the main
reference centers by clinicians who sent individual samples to the ERASPEN
Consortium or St John’s Institute of Dermatology.
Pustular psoriasis was diagnosed by expert dermatologists based on direct
clinical examination, with the ERASPEN consensus criteria1 used in at least
506 cases. The observation of primary, sterile, macroscopically visible
pustules affecting nonacral skin (GPP), palms/soles (PPP), or the nail
apparatus (ACH) was the main inclusion criterion. Conversely, the occurrence
of pustules restricted to the edges of psoriatic plaques represented an exclusion
criterion.
Mutation screening
IL36RN, AP1S3, and CARD14 mutations were screened by using Sanger
sequencing in 473 patients for whom DNAwas available. Primer sequences and
cycling conditions have been described elsewhere.3,5,6 Nucleotide substitutions
were identified by using Sequencher 4.9 (Gene Codes, Ann Arbor, Mich). The
deleterious effect of the newly identified c.11515G>A mutation was confirmed
by using Spliceman and MaxEntScan,11,12 whereas the pathogenic potential of
CARD14 alleles was assessed with Combined Annotation Dependent Depletion
(CADD).13
Statistics
The clinical and demographic characteristics of study participants were
analyzed by using a binomial test (to establish the presence of a sex bias
among patients with pustular psoriasis), the x2 test with the Yates correction
(to analyze differences in the prevalence of PV and proportion of affected
female subjects across disease types), and a Kruskal-Wallis test followed by
the Dunn multiple comparison test (to analyze differences in age of onset
between PPP, ACH, and GPP cases). Analysis of genetic data was based on
a x2 test with the Yates correction (to compare the frequency of disease alleles
in PPP, ACH, and GPP cases and the combined prevalence of IL36RN
mutations across ethnic groups) and a 1-tailed Fisher exact test (for association
between the IL36RN p.Ser113Leu allele and PPP). Genotype-phenotype
correlations were investigated by implementing logistic (for PV concurrence
and sex ratios) and linear (for age of onset) regression analysis with disease
subtype as a covariate. All tests were implemented in R software.14
Patients with multiple diagnoses were excluded from all statistical analyses
because they could not be assigned to a single disease group.
RESULTS
Age of onset and PV concurrence rates vary
significantly among disease subtypes
As members of the ERASPEN network, we previously defined
consensus criteria for the diagnosis of pustular psoriasis.1 Herewe
build on this work to describe the presentation of key diseasefeatures, as observed in clinical practice. We analyzed 863
unrelated patients, the majority of whom (823/863 [95.4%])
were recruited through 6 European, 1 North African, and 1 Asian
reference center (Table I and see Table E1). Of note, key patients’
demographics (male/female ratios and mean age of onset for
various disease types) were comparable across these
cohorts (see Table E2 in this article’s Online Repository at
www.jacionline.org).
While patients with GPP (251/863 [29.1%]) and PPP (560/863
[64.9%]) accounted for most of the data set, the ACH sample was
substantially smaller (28/863 [3.2%]), reflecting the extreme
rarity of this condition. Of note, the concurrence of multiple
disease forms (most notably GPP with ACH and GPP with PPP)
was reported in a small percentage of affected patients (24/863
[2.8%]).
A number of comorbidities were observed, with diabetes and
hypertension figuring most prominently, regardless of the
patient’s ethnicity (see Table E3 in this article’s Online
Repository at www.jacionline.org). In keeping with published
associations,15 we also found that 11 (3.9%) of 281 European
patients with PPP had autoimmune thyroid disease.
Mean age of onset differed considerably across disease types
and was lower in patients with GPP (31.0 6 19.7 years) than in
those with PPP (43.7 6 14.4, P 5 9.3 3 10219) and those
with ACH (51.8 6 20.4, P 5 1.2 3 1027; Fig 1, A, and see
Table E2). Despite these marked differences, there was
substantial heterogeneity within the individual disease cohorts,
with very early-onset (<10 years) and very late-onset
(>70 years) cases observed in all forms of pustular psoriasis.
Although the prevalence of PV in the overall data set (29.1%)
was much greater than that reported for the general population
(2% to 3%), concurrence rates varied among disease variants. In
particular, the frequency of PV among patients affected by PPP
(15.8%) was significantly lower than that seen in the ACH
(46.2%, P 5 .0004) and GPP (54.4%, P 5 2.2 3 10216) groups
(Fig 1, B). Although the latter result was driven in part by a
very high prevalence of PV among Malaysian patients with
GPP (see Table E2), the difference remained significant
(P 5 .01) when the sizeable Malaysian cohort (n 5 138) was
removed from the analysis. Thus our investigations have
demonstrated key differences between disease subtypes,
highlighting PPP as a late-onset condition with low PV
concurrence.PPP is the form of pustular psoriasis most
influenced by sex and smoking status
It has been reported that female patients and smokers are at
greater risk of PPP than male patients and nonsmokers.16 Here we
observed a degree of sex bias in all forms of pustular psoriasis as
the female/male ratiowas 1.5 in patients with ACH, 1.7 in patients
with GPP, and 3.5 in patients with PPP. The distortion in sex ratios
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FIG 1. Features of pustular psoriasis observed in the disease cohort.
A, Mean age of onset was compared across disease groups by using
a Kruskal-Wallis test followed by the Dunn multiple comparison test.
B, Differences in PV concurrence were analyzedwith a x2 test. C, Differences
in the proportion of affected female subjects were assessed by using a x2
test. The dashed line indicates the percentage of female subjects in the
general population. D, Differences in combined frequency of IL36RN
mutations were assessed across ethnic groups by using a x2 test. Pairwise
comparisons were undertaken with the Fisher exact test. The analysis was
restricted to patients with GPP because this is the only group for which data
were available for multiple ethnicities. Other mutations indicates alleles
seen only once in the cohort. The notation c.11516T>C; p.Pro76Leu refers
to patients carrying the 2 variants on the same haplotype. E, Effects of
IL36RN mutations on age of onset were assessed by using linear
regression. **P < .01, ***P < .001, and ****P < .0001.
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4 TWELVES ET ALobserved in GPP and PPP was statistically significant (P < 1025
and P < 10215, respectively) and readily recognizable in
individual cohorts (see Table E2). Of note, the difference between
the PPP and GPP female/male ratios was also significant
(P 5 5.8 3 1025), highlighting PPP as the condition most
influenced by sex-related factors (Fig 1, C).
In our data set 79.8% (249/312) of patients with PPP for whom
data were available were current or past smokers. Of interest, the
rate of PV concurrence was much greater in patients with PPP
who smoked (or had done so in the past) compared with thosewhodid not (12.4% vs 1.6%, P 5 .009), suggesting that cigarette
smoking can modulate disease manifestations. In fact, smoking
has a well-documented effect on aryl hydrocarbon
receptor signaling,17 a pathway that modulates the severity of
inflammation in psoriatic skin.18
Although the ACH sample was too small for analysis, the
percentage of smokers in the GPP data set (26/96 [28.3%]) was
significantly less than that observed in patients with PPP
(P < 10215), indicating that the adverse effect of cigarette
smoking is specific to the latter condition.
Definition of a patient subset for genetic analysis
Having investigated the key clinical manifestations of pustular
psoriasis, we sought to define their relationship with the patient’s
genotype. For this purpose, we examined the mutation status
of 473 affected subjects for whom DNA was available (see
Table E1). We collated genetic data previously generated by our
group (n 5 358)4-6,9 while also examining 115 newly recruited
cases. Importantly, Table E4 in this article’s Online Repository
at www.jacionline.org shows that the patient subset screened for
mutations is representative of the broader data set, suggesting
that the findings obtained in this sample can be generalized to
the whole resource.Frequency of IL36RN mutations differentiates PPP
from ACH and GPP
The IL36RN coding sequence and exon/intron junctions were
screened in the entire patient resource, uncovering 66 patients
(4 with ACH, 45 with GPP, 12 with PPP, and 5 with multiple
diagnoses) with disease alleles (Table II and see Table E5
in this article’s Online Repository at www.jacionline.org).
Thirty-six of these subjects harbored biallelic (homozygous/
compound heterozygous) changes, with the remaining 30
carrying monoallelic (single heterozygous) variants. All the
observed mutations had been described previously, except for a
c.11515G>A splicing variant uncovered in a North American
patient with GPP (see Table E5).
IL36RN disease alleles were present in a variety of ethnic
groups, with the greatest prevalence observed among patients of
European (34.7%) and East Asian (28.8%) descent (Fig 1, D).
Althoughwe did not detect any rare changes in the 21 South Asian
cases we examined, a homozygous p.Leu21Promutation has been
described in a Pakistani GPP pedigree,19 suggesting that
deleterious IL36RN alleles can also be found within the Indian
subcontinent.
The proportion of subjects harboring IL36RN disease alleles
was greater in GPP and ACH (23.7% and 18.2%, respectively)
compared to PPP (5.2%). Patients with GPP and those with
ACH were also more likely to carry biallelic mutations compared
to individuals affected by PPP (see Table E5). As a result, the
prevalence of IL36RN mutations was significantly increased in
patients with GPP (0.19) and ACH (0.16) compared with that in
patients with PPP (0.03;P5 1.93 10214 and .0018, respectively;
Table II). Nonetheless, the association between IL36RN
mutations and PPP, which has been recently questioned,10 was
statistically significant. In fact, an analysis of the recurrent
p.Ser113Leu variant showed that its frequency in British
patients was almost 10 times greater than that observed in
population-matched control subjects (P5 9.33 1028; odds ratio,
10.8; 95% CI, 5.3-22.0; Table III).
TABLE II. IL36RN and AP1S3 mutation frequencies across disease types
ACH GPP PPP Multiple diagnoses
No. of IL36RN-positive patients* 4/23 (17.4%) 45/190 (23.7%) 12/234 (5.1%) 5/18 (27.8%)
IL36RN mutation count (frequency) 7/46 (0.15) 72/380 (0.19) 15/468 (0.03) 8/36 (0.22)
No. of AP1S3-positive patients* 2/19 (10.5%) 4/37 (10.8%) 14/212 (6.6%) 4/11 (36.4%)
AP1S3 mutation count (frequency) 2/38 (0.05) 4/74 (0.05) 14/424 (0.03) 4/22 (0.18)
*Patients were classified as ‘‘positive’’ if they were carrying at least 1 mutation at the examined locus.
p.Phe4Cys and p.Arg33Trp mutations have no frequency in East Asian populations and therefore were not screened in patients from this ethnic group.
TABLE III. Association between IL36RN p.Ser113Leu and PPP
p.Ser113Leu WT
Cases* 11 (3.6%) 291 (96.4%)
Control subjects 26 (0.4%) 7402 (99.6%)
WT, Wild-type.
*British patients only.
Control subjects from publicly accessible cohorts (TWINSUK and ALSPAC).
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TWELVES ET AL 5We next sought to determine whether IL36RN alleles were
associated with key features of pustular psoriasis across
disease subtypes. Therefore we implemented a regression
analysis using clinical diagnosis as a covariate. Although we
did not observe a consistent effect of IL36RN mutations on
PV concurrence (see Table E6 in this article’s Online
Repository at www.jacionline.org), we found a significant
association with early age of onset (P 5 .003; Fig 1, E), which
was observed in all 3 forms of the disease (see Table E6). Thus
IL36RN alleles have shared genetic effects across pustular
psoriasis subtypes but occur at a very low frequency among
patients with PPP.CARD14 mutations are observed in only a small
minority of cases
Although a sizeable patient subset (n 5 106/473) was
sequenced for the entire CARD14 coding region, a targeted
screening of exons 3 and 4 was undertaken in the rest of the
sample, given that the only disease alleles associated with
pustular (p.Asp176His) or plaque (p.Gly117Ser) psoriasis map
to this mutation hotspot.6,20,21
We found 3 previously described6 GPP patients of Chinese
descent bearing the p.Asp176His variant. We did not detect any
CARD14 substitutions among European patients with GPP
but observed 5 British patients with PPP harboring rare
nonsynonymous changes with deleterious potential (see Table
E7 in this article’s Online Repository at www.jacionline.org).
Although most of the above subjects (6/8 [75%]) had concurrent
PV, the small size of the data set prevented us from establishing
genotype-phenotype correlations.AP1S3 mutations occur with comparable frequency
across disease types
Although a substantial patient subset (n5 249)was screened for
the entire coding region, the rest were sequenced only for exon 2,
given that the only known AP1S3 mutations (p.Phe4Cys,
p.Arg33Trp) map to this genomic segment 2.5,9 This revealed 24
European cases (2 patients with ACH, 4 with GPP, 14 with PPP,
and 4 with multiple diagnoses) bearing the p.Phe4Cys or
p.Arg33Trp changes (see Table E8 in this article’s OnlineRepository at www.jacionline.org). No additional mutations were
observed in the subjects who were screened for the entire coding
region. Of note, 3 patients (2 with GPP and 1 with PPP) carried
both AP1S3 and IL36RN disease alleles (see Table E9 in this
article’s Online Repository at www.jacionline.org).
The prevalence of AP1S3 mutations was not significantly
different across disease types (Table II) and did not seem to
influence PV concurrence or age of onset (see Table E10 in this
article’s Online Repository at www.jacionline.org). However, it
was noteworthy that almost all patients with AP1S3 disease
alleles (23/24 [95.8%]) were female. Although this observation
was not statistically significant (P 5 .06), a trend toward female
overrepresentation was apparent in all clinical variants
(see Table E10), suggesting that the penetrance of AP1S3
mutations might be modified by sex-specific factors, such as
hormone levels or X-linked modifiers.DISCUSSION
The purpose of our study was to robustly define clinical and
genetic features of pustular psoriasis by investigating a patient
cohort of unprecedented size.
Initially, we sought to define the presentation of the various
clinical variants through a rigorous statistical analysis of key
phenotypic features. This work, which builds on the definition of
consensus diagnostic criteria by ERASPEN,1 underscores the
importance of collaborative efforts in the analysis of rare diseases.
Here a common case report form was used in all prospectively
recruited cases, enabling standardized patient phenotyping and
robust data collection. The participation of multiple centers also
allowed us to monitor the effects of ascertainment bias and
show that key patients’ demographics were comparable across
the various data sets.
Our analysis demonstrated novel and significant differences
between disease subtypes. Specifically, it showed that PPP is
associated with patients’ demographics (very high prevalence of
female subjects and smokers), clinical (low rates of PV) and
genetic features (low prevalence of IL36RN mutations) that are
clearly distinct from those observed in ACH and GPP. Given
that abnormal IL-36 signaling has now been implicated in the
pathogenesis of plaque psoriasis,22 it is tempting to speculate
that these observations might be correlated with each other and
that the decreased prevalence of PV in PPP might be linked to
the low frequency of deleterious IL36RN alleles in this patient
group.
We also found that IL36RN mutations are associated with an
earlier age of onset across all variants of pustular psoriasis. This
validates the results we obtained originally in patients with
GPP4 and indicates that IL36RN should be prioritized for
mutation screening when patients have disease symptoms before
J ALLERGY CLIN IMMUNOL
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6 TWELVES ET ALthe age of 30 years (40 years in the case of ACH/PPP). Given that
biologics that counter the effect of IL36RNmutations by blocking
IL-36 signaling are now under development,23 such targeted
screening could have important implications for patient
management.
Our study showed that IL36RNmutations are the most frequent
genetic abnormality observed in pustular psoriasis. In fact,
deleterious AP1S3 alleles were found in only 7% to 10% of
patients, and CARD14 variants were observed in a very small
number of affected subjects. Importantly, our analysis
demonstrated that known genes account only for a minority of
disease cases. This is especially the case in patients with PPP,
in whom the combined frequency of AP1S3 and IL36RN
mutations is less than 10%. Therefore additional studies will be
needed to illuminate the genetic landscape of this condition,
facilitate its diagnosis, and better understand the correlation
between genotype and clinical phenotype. Although the
discovery of novel genetic determinants has thus far been
hindered by the rarity and heterogeneous nature of the disease,
the ascertainment and rigorous phenotyping of our clinical
resource lays a robust foundation for future gene identification
studies.
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Clinical implications: The association between IL36RN
mutations and early-onset pustular psoriasis defines a patient
group that should be prioritized for IL36RN screening and
might benefit from the development of IL-36 inhibitors.REFERENCES
1. Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Koks S, et al. European
consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Ve-
nereol 2017;31:1792-9.
2. Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-
36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med
2011;365:620-8.
3. Onoufriadis A, Simpson MA, Pink AE, Di Meglio P, Smith CH, Pullabhatla V,
et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflam-
matory skin disease known as generalized pustular psoriasis. Am J Hum Genet
2011;89:432-7.
4. Hussain S, Berki DM, Choon SE, Burden AD, Allen MH, Arostegui JI, et al.
IL36RN mutations define a severe auto-inflammatory phenotype of generalized
pustular psoriasis. J Allergy Clin Immunol 2015;135:1067-70.
5. Setta-Kaffetzi N, Simpson MA, Navarini AA, Patel VM, Lu HC, Allen MH, et al.
AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like re-
ceptor 3 trafficking. Am J Hum Genet 2014;94:790-7.
6. Berki DM, Liu L, Choon SE, David Burden A, Griffiths CE, Navarini AA, et al.
Activating CARD14 mutations are associated with generalized pustular psoriasis
but rarely account for familial recurrence in psoriasis vulgaris. J Invest Dermatol
2015;135:2964-70.
7. Mossner R, Frambach Y, Wilsmann-Theis D, Lohr S, Jacobi A, Weyergraf A, et al.
Palmoplantar pustular psoriasis is associated with missense variants in CARD14,
but not with loss-of-function mutations in IL36RN in European patients. J Invest
Dermatol 2015;135:2538-41.
8. Setta-Kaffetzi N, Navarini AA, Patel VM, Pullabhatla V, Pink AE, Choon SE, et al.
Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated
pustular phenotypes. J Invest Dermatol 2013;133:1366-9.
9. Mahil SK, Twelves S, Farkas K, Setta-Kaffetzi N, Burden AD, Gach JE, et al.
AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte auto-
phagy and up-regulating IL-36 production. J Invest Dermatol 2016;136:2251-9.
10. M€ossner R, Wilsmann-Theis D, Oji V, Gkogkolou P, L€ohr S, Schulz P, et al. The
genetic basis for most patients with pustular skin disease remains elusive. Br J Der-
matol 2018;178:740-8.
11. Lim KH, Fairbrother WG. Spliceman—a computational web server that predicts
sequence variations in pre-mRNA splicing. Bioinformatics 2012;28:1031-2.
12. Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with ap-
plications to RNA splicing signals. J Comput Biol 2004;11:377-94.
13. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general
framework for estimating the relative pathogenicity of human genetic variants.
Nat Genet 2014;46:310-5.
14. R Core Team. R: a language and environment for statistical computing. Vienna: R
Foundation for Statistical Computing; 2017.
15. Mrowietz U, van de Kerkhof PC. Management of palmoplantar pustulosis: do we
need to change? Br J Dermatol 2011;164:942-6.
16. Burden AD, Kirby B. Psoriasis and related disorders. In: Griffiths CEM, Barker JN,
Bleiker T, Chalmers RJ, Creamer D, editors. Rook’s textbook of dermatology. Chi-
chester: Wiley-Blackwell; 2016.
17. Chen Y, Widschwendter M, Teschendorff AE. Systems-epigenomics inference of
transcription factor activity implicates aryl-hydrocarbon-receptor inactivation as
a key event in lung cancer development. Genome Biol 2017;18:236.
18. Di Meglio P, Duarte JH, Ahlfors H, Owens ND, Li Y, Villanova F, et al. Activation
of the aryl hydrocarbon receptor dampens the severity of inflammatory skin condi-
tions. Immunity 2014;40:989-1001.
19. Ellingford JM, Black GC, Clayton TH, Judge M, Griffiths CE, Warren RB. A novel
mutation in IL36RN underpins childhood pustular dermatosis. J Eur Acad Derma-
tol Venereol 2016;30:302-5.
20. Jordan CT, Cao L, Roberson ED, Pierson KC, Yang CF, Joyce CE, et al. PSORS2 is
due to mutations in CARD14. Am J Hum Genet 2012;90:784-95.
21. Sugiura K, Muto M, Akiyama M. CARD14 c.526G>C (p.Asp176His) is a signif-
icant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Jap-
anese cohort. J Invest Dermatol 2014;134:1755-7.
22. Mahil SK, Catapano M, Di Meglio P, Dand N, Ahlfors H, Carr IM, et al. An anal-
ysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations val-
idates IL-36 as a psoriasis therapeutic target. Sci Transl Med 2017;9:eaan2514.
23. Ganesan R, Raymond EL, Mennerich D, Woska JR, Caviness G, Grimaldi C, et al.
Generation and functional characterization of anti-human and anti-mouse IL-36R
antagonist monoclonal antibodies. MAbs 2017;9:1143-54.
